Post hoc analysis shows no systematic wearing-off effects with erenumab Erenumab disappoints in trigeminal neuralgia Real-world economic data support CGRP mAbs in migraine Favourable 1-year safety and tolerability for zavegepant in acute migraine treatment PROGRESS results support atogepant benefits in chronic migraine prevention Predictors of galcanezumab response Need for continued CGRP mAb treatment in chronic migraine cAMP-evoked migraine attacks act downstream of CGRP receptor

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2022 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |